Leptin Role in Advanced Lung Cancer. A Mediator of the Acute Phase Response or a Marker of the Status of Nutrition?

Alemán, Marı́a Remedios; Santolaria, Francisco; Batista, Norberto; Vega, María José; González‐Reimers, Emilio; Milena, Antonio; Llanos, Marta; Gómez-Sirvent, Juan Luís

doi:10.1006/cyto.2002.1051

Cited by 110 publications

(88 citation statements)

References 27 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, an interesting fi nding was that serum leptin levels showed a signifi cant effect on the overall survival of lung cancer patients. Lower leptin levels at diagnosis were followed by shorter survival; this fi nding is in agreement with the results presented by Aleman et al Study (11). The results in our study did not show that serum leptin could play a potential role as a prognostic marker in response to chemotherapy.…”

Section: Discussionsupporting

confidence: 93%

“…In both Aleman's (11) and Werynska's study (22), the higher serum leptin concentration was combined with better nutrition. The results of Aleman et al (11) who found a positive leptin correlation with such factors as BMI and body fat mass are similar to those of our study. Our fi ndings suggest that serum leptin level was not a reliable indicator of prognosis in patients with non-small cell lung carcinoma like Tas et al There are several limitations to our study.…”

Section: Discussionsupporting

confidence: 93%

“…Regarding leptin, our fi nding of its decreased circulating levels in the patient group is in accordance with the majority of related studies that have found statistically signifi cant results (11,12,13). On the contrary, there are some studies with elevated levels of leptin (7,8).…”

Section: Discussionsupporting

confidence: 91%

See 2 more Smart Citations

Are serum leptin levels a prognostic factor in advanced lung cancer?

Anar¹,

Deniz²,

Erol³

et al. 2017

BLL

View full text Add to dashboard Cite

AIM: The aim of the present study was to evaluate pre-treatment concentrations of leptin in patients with advanced lung cancer and to investigate possible associations between their levels and clinicopathological variables, response to therapy and overall survival. MATERIAL AND METHODS: There are 71 previously untreated patients with cytological or histological evidence of primary lung cancer who were admitted to the oncology department between November 2013 and August 2014. Forty-fi ve healthy individuals with age, sex and BMI matching the lung cancer patients, were recruited to take part in the study as a control group. Leptin levels were measured quantitatively by using a microELISA kit. RESULTS: The serum leptin levels at diagnosis were signifi cantly lower in lung cancer patients than those in control subjects (4.75 ± 4.91 ng/ml, 9.67 ± 8.02 ng/ml; p < 0.001). We did not fi nd any signifi cant difference in leptin values related to clinicopathological parameters such as ECOG PS, weight loss, histological type, disease stage and TNM classifi cation. Nevertheless, we demonstrated a signifi cant correlation between serum leptin levels and BMI in lung cancer patients (correlation coeffi cient: 0.303; p > 0.010). The analysis of serum leptin values did not show any association with the overall survival of the patients. CONCLUSION: Our results showed that the serum leptin level has no prognostic indications in advanced lung cancer patients. Leptin is decreased in lung cancer, and there is lack of correlation with tumour-related factors including prognosis. Therefore, leptin is not a useful clinical marker in lung cancer (Tab. 2, Fig. 2, Ref. 22). Text in PDF www.elis.sk.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Are serum leptin levels a prognostic factor in advanced lung cancer?

Anar¹,

Deniz²,

Erol³

et al. 2017

BLL

View full text Add to dashboard Cite

show abstract

“…In addition, administration of TNF in animals has been shown to lead to the reduction of MyHC mRNA (58), although under these conditions the effect may be secondary to the direct activity of the cytokine. Whether circulating levels of TNF or IFN are elevated in cancer patients is controversial, but studies do support their relevance in wasting (11)(12)(13)(14)(15). There is also evidence that cytokines may rise as a consequence of the cancer therapy itself.…”

Section: Figurementioning

confidence: 99%

“…These factors are produced by host immune cells in response to the tumor, or by tumor cells themselves. TNF-α in particular (formerly named cachectin and from here on referred to as TNF) has been found to be elevated in the circulation of cancer patients (11)(12)(13)(14)(15) and is thought to contribute to multiple aspects of cachexia (16). For example, TNF potently stimulates fat degeneration (17,18) and plays a key role in tumor-induced muscle wasting (19)(20)(21)(22)(23)(24).…”

Section: Introductionmentioning

confidence: 99%

Cancer cachexia is regulated by selective targeting of skeletal muscle gene products

Acharyya¹,

Ladner²,

Nelsen³

et al. 2004

J. Clin. Invest.

398

231

View full text Add to dashboard Cite

Cachexia is a syndrome characterized by wasting of skeletal muscle and contributes to nearly one-third of all cancer deaths. Cytokines and tumor factors mediate wasting by suppressing muscle gene products, but exactly which products are targeted by these cachectic factors is not well understood. Because of their functional relevance to muscle architecture, such targets are presumed to represent myofibrillar proteins, but whether these proteins are regulated in a general or a selective manner is also unclear. Here we demonstrate, using in vitro and in vivo models of muscle wasting, that cachectic factors are remarkably selective in targeting myosin heavy chain. In myotubes and mouse muscles, TNF-α plus IFN-γ strongly reduced myosin expression through an RNA-dependent mechanism. Likewise, colon-26 tumors in mice caused the selective reduction of this myofibrillar protein, and this reduction correlated with wasting. Under these conditions, however, loss of myosin was associated with the ubiquitin-dependent proteasome pathway, which suggests that mechanisms used to regulate the expression of muscle proteins may be cachectic factor specific. These results shed new light on cancer cachexia by revealing that wasting does not result from a general downregulation of muscle proteins but rather is highly selective as to which proteins are targeted during the wasting state.

show abstract

Anorexia and Cachexia

Ohnuma

2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Cancer cachexia is a wasting syndrome with extensive loss of skeletal muscle mass with or without adipose tissue. It may be contrasted with simple starvation in which fat replaces glucose as the preferred fuel to spare lean body mass. It results from altered metabolism rather than just an energy deficit, and cannot be reversed by conventional nutritional support. The causes of cancer‐related cachexia are multifactorial including production of procachectic cytokines and metabolic derangements. European cancer community is credited in developing new definition and classification of cancer cachexia. Recent studies identified anamorelin, an oral ghrelin analogue, as a new agent for the treatment of cancer cachexia.

show abstract

Leptin Role in Advanced Lung Cancer. A Mediator of the Acute Phase Response or a Marker of the Status of Nutrition?

Cited by 110 publications

References 27 publications

Are serum leptin levels a prognostic factor in advanced lung cancer?

Are serum leptin levels a prognostic factor in advanced lung cancer?

Cancer cachexia is regulated by selective targeting of skeletal muscle gene products

Anorexia and Cachexia

Contact Info

Product

Resources

About